Tecovirimat

Edina Avdic, Pharm.D.
Tecovirimat is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or purchase a subscription.

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

Pediatrics Central

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Indicated for the treatment of human smallpox disease in adults and pediatric patients weighing at least 13 kg.
    • Limitation of use:
      • Effectiveness of tecovirimat treatment of smallpox disease has not been determined in humans because adequate and well-controlled field trials have not been feasible, and inducing smallpox disease in humans to study the drug’s efficacy is not ethical.
      • Efficacy may be reduced in immunocompromised patients based on animal models.

-- To view the remaining sections of this topic, please or purchase a subscription --

Last updated: September 6, 2019